| http://www.w3.org/ns/prov#value | - including alemtuzumab-MS, mipomersen and eliglustat tartrate for any reason, including trial results that are not as favorable as expected and safety profiles that reduce the potential target population; that Genzyme is unable to complete any or all of its planned business divestitures by the end of the year; and the risks and uncertainties described in Genzyme's SEC reports filed under the Secur
|
